Compare BioNTech SE - ADR (BNTX) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Halliburton Company — how do they compare? BioNTech SE - ADR trades at $93.19 (market cap $23.31B), while Halliburton Company trades at $33.54 (market cap $28.16B). The key difference: Halliburton Company is the larger of the two by market cap, and Halliburton Company pays a 2.01% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | HAL | |
|---|---|---|
Market Cap | $23.31B | $28.16B |
Sector | Health | Energy |
52-Week High | $119.34 | $42.98 |
52-Week Low | $83.89 | $20.97 |
Enterprise Value | $6.60B | $34.31B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Halliburton (HAL) trades at $33.6, down slightly (-0.12%) on the day. The stock shows a bullish technical signal overall, with recent earnings beats in Q1 and Q2 2026. Revenue for 2025 was $22.18B with a net income margin of 7.16%, though this declined from 2024. The company maintains solid profitability with a 14.89% ROE and recently announced partnerships, including an AI data center-linked gas project in Australia (Reuters, 2026-07-29).
The outlook is supported by a strong analyst consensus (73% Buy ratings) and a $43.60 price target, implying significant upside. Key risks include geopolitical tensions impacting Middle East operations and a potentially softening oilfield services market. Earnings growth from international contract wins remains a primary catalyst for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
